CBIO
Crescent Biopharma
CBIO
CBIO
34 hedge funds and large institutions have $14.3M invested in Crescent Biopharma in 2022 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 5 closing their positions.
New
Increased
Maintained
Reduced
Closed
less ownership
Funds ownership: →
less funds holding
Funds holding: →
less capital invested
Capital invested by funds: $ → $
less first-time investments, than exits
New positions opened: | Existing positions closed:
33% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 6
Holders
34
Holding in Top 10
–
Calls
$6K
Puts
–
Top Buyers
| 1 | +$18K | |
| 2 | +$17.8K | |
| 3 | +$10K | |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$10K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$6.67K |
Top Sellers
| 1 | -$112K | |
| 2 | -$60.9K | |
| 3 | -$51.9K | |
| 4 |
Millennium Management
New York
|
-$37.7K |
| 5 |
Charles Schwab
San Francisco,
California
|
-$37K |